Aurinia Pharmaceuticals (NASDAQ:AUPH) Price Target Raised to $18.00

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) had its price target lifted by research analysts at Royal Bank Of Canada from $16.00 to $18.00 in a note issued to investors on Monday, Benzinga reports. The firm currently has a “sector perform” rating on the biotechnology company’s stock. Royal Bank Of Canada‘s target price would suggest a potential upside of 10.35% from the company’s current price.

A number of other research analysts have also weighed in on the company. Bloom Burton upgraded Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th. TD Cowen increased their price target on shares of Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. Wall Street Zen cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Aurinia Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 22nd. Finally, Zacks Research cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 21st. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Aurinia Pharmaceuticals Trading Down 2.0%

AUPH stock traded down $0.34 during midday trading on Monday, reaching $16.31. The company’s stock had a trading volume of 13,817 shares, compared to its average volume of 1,143,831. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.97 and a current ratio of 5.42. The firm has a market capitalization of $2.17 billion, a price-to-earnings ratio of 7.21 and a beta of 1.60. The stock has a fifty day simple moving average of $16.49 and a two-hundred day simple moving average of $15.64. Aurinia Pharmaceuticals has a 1 year low of $12.79 and a 1 year high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Friday, October 30th. The biotechnology company reported $0.23 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $0.01. The company had revenue of $83.70 million during the quarter, compared to analyst estimates of $83.61 million. Aurinia Pharmaceuticals had a return on equity of 23.67% and a net margin of 97.68%. On average, equities research analysts predict that Aurinia Pharmaceuticals will post 0.91 EPS for the current year.

Hedge Funds Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AUPH. BlackRock Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 2nd quarter worth $139,037,000. Renaissance Technologies LLC raised its holdings in Aurinia Pharmaceuticals by 4.6% in the first quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock valued at $24,658,000 after acquiring an additional 73,700 shares in the last quarter. Allianz Asset Management GmbH bought a new position in shares of Aurinia Pharmaceuticals during the second quarter worth about $14,284,000. Janus Henderson Group PLC grew its position in shares of Aurinia Pharmaceuticals by 9.7% in the 1st quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company’s stock worth $11,225,000 after acquiring an additional 66,806 shares in the last quarter. Finally, Jupiter Topco LLC bought a new stake in Aurinia Pharmaceuticals during the second quarter valued at $10,219,000. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s principal product is Lupkynis (voclosporin), an oral calcineurin inhibitor used in combination with other immunosuppressive therapies to treat adults with active lupus nephritis, a serious kidney complication of systemic lupus erythematosus.

Voclosporin was approved by the U.S. Food and Drug Administration in 2021, making Lupkynis the first oral therapy specifically approved in the United States for adult patients with active lupus nephritis.